Li Zhiming, chairman of China National Medicine Holdings, suddenly resigned for "personal reasons". At the end of last month, the coronary vaccine developed by the company's company's company had just been officially approved to be listed.
The announcement issued by Chinese Medicine Holdings on the official website of the Hong Kong Stock Exchange last night (12th) showed that the board of directors received the resignation of chairman Li Zhiming on January 12.For personal reasons, Li Zhiming proposed to the board of directors to resign from the company's chairman, executive director, chairman of the board nomination committee, chairman of the board of directors of the board of directors, and members of the board of directors.
Announcement stated that Li Zhiming confirmed that he had no "disagreement" with the board of directors, and nor had nothing to resign.
Sinopharm Holdings emphasized in the announcement that the company's current directors and management management have performed their duties normally, and the company's production and operation is normal.
According to the announcement, the Board of Directors of the Sinopharm Holdings has elected the chairman of the Qingming for its powers in accordance with the company's articles of association.
According to the official website of Chinese Medicine Holdings, Yu Qingming is the secretary of the party committee and executive director of the Chinese Medicine Holdings.
Sinopharm Holdings is the core enterprise of China Sinopharm Group. It is the largest pharmaceutical, medical care and medical device wholesaler and retailers in China. It was listed in Hong Kong in 2009.
On December 31st last year, the crown disease of China Biological Beijing Corporation, a subsidiary of Sinopharm Group, was approved for listing. It was the first domestic crown vaccine that was officially approved by China.
